Comparison · NCT02264613-340db9de
Dose Regimen A (DR-A) PTCL Expansion vs Dose Regimen C (DR-C) PTCL Expansion: Determine Overall Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dose Regimen A (DR-A) PTCL Expansion vs Dose Regimen C (DR-C) PTCL Expansion: Determine Overall Response Rate. Trial comparisons, record NCT02264613-340db9de. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02264613-340db9de
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0952 | 0.0265 | 0.289 | wilson | |
| Risk in group 2 | 0.125 | 0.035 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0298 | -0.275 | 0.184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.762 | 0.12 | 4.84 | log | |
| Odds ratio, group 1 over group 2 | 0.737 | 0.0922 | 5.89 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dose Regimen A (DR-A) PTCL Expansion than on Dose Regimen C (DR-C) PTCL Expansion | 33.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dose Regimen A (DR-A) PTCL Expansion | Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.~ALRN-6924: ALRN-6924 will be administered as an IV infusion | 2 | 21 | OG000 |
| Group 2 | Dose Regimen C (DR-C) PTCL Expansion | Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle~ALRN-6924: ALRN-6924 will be administered as an IV infusion | 2 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Determine Overall Response Rate
- Description
The proportion of efficacy-evaluable patients who achieve complete response (CR) or partial response (PR), per investigator assessment, in accordance with RECIST 1.1 or iRECIST (for solid tumor patients) or Response Assessment in Neuro-Oncology (RANO) criteria (for glioblastoma patients).
- Time frame
- From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days
- Population
Source ClinicalTrials.gov
Trial
- Title
- ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
- NCT number
- NCT02264613
- Phases
- PHASE1, PHASE2
- Conditions
- Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
- Interventions
- ALRN-6924
- Lead sponsor
- Aileron Therapeutics, Inc.
- Results first posted
- 2026-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02264613?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02264613-340db9de